<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231020203606&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231020203606&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 21 Oct 2023 00:36:07 +0000</lastbuilddate>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Intravascular ultrasound for actual bioprosthetic heart valve expansion during transcatheter bicuspid aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37862595/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 20:ehad683. doi: 10.1093/eurheartj/ehad683. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37862595/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37862595</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad683>10.1093/eurheartj/ehad683</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37862595</guid>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Łukasz Kalińczuk</dc:creator>
<dc:creator>Wiktor Skotarczak</dc:creator>
<dc:creator>Lars Sondergaard</dc:creator>
<dc:creator>Gary S Mintz</dc:creator>
<dc:date>2023-10-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravascular ultrasound for actual bioprosthetic heart valve expansion during transcatheter bicuspid aortic valve replacement</dc:title>
<dc:identifier>pmid:37862595</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad683</dc:identifier>
</item>
<item>
<title>Deep learning approach to unmask hidden salt effects in the era of artificial intelligence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37862594/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 20:ehad673. doi: 10.1093/eurheartj/ehad673. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37862594/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37862594</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad673>10.1093/eurheartj/ehad673</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37862594</guid>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Athanasios J Manolis</dc:creator>
<dc:creator>Manolis S Kallistratos</dc:creator>
<dc:date>2023-10-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning approach to unmask hidden salt effects in the era of artificial intelligence</dc:title>
<dc:identifier>pmid:37862594</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad673</dc:identifier>
</item>
<item>
<title>Tracking changes in 'healthy sleep' for cardiovascular risk assessment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37862588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 20:ehad509. doi: 10.1093/eurheartj/ehad509. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37862588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37862588</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad509>10.1093/eurheartj/ehad509</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37862588</guid>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Sevasti-Maria Chaldoupi</dc:creator>
<dc:date>2023-10-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tracking changes in 'healthy sleep' for cardiovascular risk assessment</dc:title>
<dc:identifier>pmid:37862588</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad509</dc:identifier>
</item>
<item>
<title>Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37862581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 20:ehad660. doi: 10.1093/eurheartj/ehad660. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37862581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37862581</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad660>10.1093/eurheartj/ehad660</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37862581</guid>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Juan Tamargo</dc:creator>
<dc:creator>Stefan Agewall</dc:creator>
<dc:date>2023-10-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated</dc:title>
<dc:identifier>pmid:37862581</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad660</dc:identifier>
</item>
<item>
<title>Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37860863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDLR (LDL receptor) function. Given that severely elevated LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating a largely unmet need for aggressive LDLR-independent lipid-lowering therapies in young patients with HoFH. Here we present the first evaluation of the efficacy and safety of evinacumab, a novel LDLR-independent lipid-lowering therapy, in pediatric patients with HoFH from parts A and B of a 3-part study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The phase 3, part B, open-label study treated 14 patients 5 to 11 years of age with genetically proven HoFH (true homozygotes and compound heterozygotes) with LDL-C >;130 mg/dL, despite optimized lipid-lowering therapy (including LDLR-independent apheresis and lomitapide), with intravenous evinacumab 15 mg/kg every 4 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Evinacumab treatment rapidly and durably (through week 24) decreased LDL-C with profound reduction in the first week, with a mean (SE) LDL-C reduction of -48.3% (10.4%) from baseline to week 24. ApoB (mean [SE], -41.3% [9.0%]), non-high-density lipoprotein cholesterol (-48.9% [9.8%]), and total cholesterol (-49.1% [8.1%]) were similarly decreased. Treatment-emergent adverse events were reported in 10 (71.4%) patients; however, only 2 (14.3%) reported events were considered to be treatment-related (nausea and abdominal pain). One serious treatment-emergent adverse event of tonsillitis occurred (n=1), but this was not considered treatment-related.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT04233918.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37860863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37860863</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065529>10.1161/CIRCULATIONAHA.123.065529</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37860863</guid>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Albert Wiegman</dc:creator>
<dc:creator>Susanne Greber-Platzer</dc:creator>
<dc:creator>Shazia Ali</dc:creator>
<dc:creator>M Doortje Reijman</dc:creator>
<dc:creator>Eliot A Brinton</dc:creator>
<dc:creator>Min-Ji Charng</dc:creator>
<dc:creator>Shubha Srinivasan</dc:creator>
<dc:creator>Carissa Baker-Smith</dc:creator>
<dc:creator>Seth Baum</dc:creator>
<dc:creator>Julie A Brothers</dc:creator>
<dc:creator>Jacob Hartz</dc:creator>
<dc:creator>Patrick M Moriarty</dc:creator>
<dc:creator>Jeanne Mendell</dc:creator>
<dc:creator>Sébastien Bihorel</dc:creator>
<dc:creator>Poulabi Banerjee</dc:creator>
<dc:creator>Richard T George</dc:creator>
<dc:creator>Boaz Hirshberg</dc:creator>
<dc:creator>Robert Pordy</dc:creator>
<dc:date>2023-10-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia</dc:title>
<dc:identifier>pmid:37860863</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065529</dc:identifier>
</item>
<item>
<title>Healthy sleep score changes and incident cardiovascular disease in European prospective community-based cohorts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37860848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Higher HSS and HSS improvement over time are associated with a lower risk of CHD and stroke in the community.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 20:ehad657. doi: 10.1093/eurheartj/ehad657. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Evidence on the link between sleep patterns and cardiovascular diseases (CVDs) in the community essentially relies on studies that investigated one single sleep pattern at one point in time. This study examined the joint effect of five sleep patterns at two time points with incident CVD events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: By combining the data from two prospective studies, the Paris Prospective Study III (Paris, France) and the CoLaus|PsyCoLaus study (Lausanne, Switzerland), a healthy sleep score (HSS, range 0-5) combining five sleep patterns (early chronotype, sleep duration of 7-8 h/day, never/rarely insomnia, no sleep apnoea, and no excessive daytime sleepiness) was calculated at baseline and follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study sample included 11 347 CVD-free participants aged 53-64 years (44.6% women). During a median follow-up of 8.9 years [interquartile range (IQR): 8.0-10.0], 499 first CVD events occurred (339 coronary heart disease (CHD) and 175 stroke). In multivariate Cox analysis, the risk of CVD decreased by 18% [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.76-0.89] per one-point increment in the HSS. After a median follow-up of 6.0 years (IQR: 4.0-8.0) after the second follow-up, 262 first CVD events occurred including 194 CHD and 72 stroke. After adjusting for baseline HSS and covariates, the risk of CVD decreased by 16% (HR 0.84, 95% CI 0.73-0.97) per unit higher in the follow-up HSS over 2-5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Higher HSS and HSS improvement over time are associated with a lower risk of CHD and stroke in the community.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37860848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37860848</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad657>10.1093/eurheartj/ehad657</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37860848</guid>
<pubDate>Fri, 20 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Aboubakari Nambiema</dc:creator>
<dc:creator>Quentin Lisan</dc:creator>
<dc:creator>Julien Vaucher</dc:creator>
<dc:creator>Marie-Cecile Perier</dc:creator>
<dc:creator>Pierre Boutouyrie</dc:creator>
<dc:creator>Nicolas Danchin</dc:creator>
<dc:creator>Frédérique Thomas</dc:creator>
<dc:creator>Catherine Guibout</dc:creator>
<dc:creator>Geoffroy Solelhac</dc:creator>
<dc:creator>Raphael Heinzer</dc:creator>
<dc:creator>Xavier Jouven</dc:creator>
<dc:creator>Pedro Marques-Vidal</dc:creator>
<dc:creator>Jean-Philippe Empana</dc:creator>
<dc:date>2023-10-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Healthy sleep score changes and incident cardiovascular disease in European prospective community-based cohorts</dc:title>
<dc:identifier>pmid:37860848</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad657</dc:identifier>
</item>
<item>
<title>Can digital technology help deliver change in cardiovascular medicine?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37856792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 19:ehad680. doi: 10.1093/eurheartj/ehad680. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37856792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37856792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad680>10.1093/eurheartj/ehad680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37856792</guid>
<pubDate>Thu, 19 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2023-10-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Can digital technology help deliver change in cardiovascular medicine?</dc:title>
<dc:identifier>pmid:37856792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad680</dc:identifier>
</item>
<item>
<title>Management of Adults With Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37855757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>As a result of increasing adoption of imaging screening, the number of adult patients with a diagnosis of anomalous aortic origin of the coronary arteries (AAOCA) has grown in recent years. Existing guidelines provide a framework for management and treatment, but patients with AAOCA present with a wide range of anomalies and symptoms that make general recommendations of limited applicability. In particular, a large spectrum of interventions can be used for treatment, and there is no consensus on...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 16:S0735-1097(23)06455-0. doi: 10.1016/j.jacc.2023.08.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">As a result of increasing adoption of imaging screening, the number of adult patients with a diagnosis of anomalous aortic origin of the coronary arteries (AAOCA) has grown in recent years. Existing guidelines provide a framework for management and treatment, but patients with AAOCA present with a wide range of anomalies and symptoms that make general recommendations of limited applicability. In particular, a large spectrum of interventions can be used for treatment, and there is no consensus on the optimal approach to be used. In this paper, a multidisciplinary group of clinical and interventional cardiologists and cardiac surgeons performed a systematic review and critical evaluation of the available evidence on the interventional treatment of AAOCA in adult patients. Using a structured Delphi process, the group agreed on expert recommendations that are intended to complement existing clinical practice guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37855757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37855757</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.012>10.1016/j.jacc.2023.08.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37855757</guid>
<pubDate>Thu, 19 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>Antonino Di Franco</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:creator>Emile Bacha</dc:creator>
<dc:creator>Eric R Bates</dc:creator>
<dc:creator>Duke E Cameron</dc:creator>
<dc:creator>Davide Cao</dc:creator>
<dc:creator>Tirone E David</dc:creator>
<dc:creator>Ruggero De Paulis</dc:creator>
<dc:creator>Ismail El-Hamamsy</dc:creator>
<dc:creator>Kanwal M Farooqi</dc:creator>
<dc:creator>Leonard N Girardi</dc:creator>
<dc:creator>Christoph Gräni</dc:creator>
<dc:creator>Jonathan D Kochav</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>John D Puskas</dc:creator>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>James Tatoulis</dc:creator>
<dc:creator>Quynh A Truong</dc:creator>
<dc:creator>Jonathan W Weinsaft</dc:creator>
<dc:creator>Daniel Zimpfer</dc:creator>
<dc:creator>Carlos M Mery</dc:creator>
<dc:date>2023-10-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Adults With Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37855757</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.012</dc:identifier>
</item>
<item>
<title>Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37855144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: In this cohort of middle-aged and older adults, PVC count during submaximal exercise and recovery were both associated with MI/HF/LTVA, all-cause mortality, HF, LTVAs, and cardiovascular mortality, independent of clinical and exercise test factors, indicating an incremental increase in risk as PVC count rises. Complex PVC rhythms were associated with higher risk compared with PVC count alone. Underlying mechanisms may include the presence of subclinical cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 19. doi: 10.1161/CIRCULATIONAHA.123.064633. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The consequences of exercise-induced premature ventricular contractions (PVCs) in asymptomatic individuals remain unclear. This study aimed to assess the association between PVC burdens during submaximal exercise and major adverse cardiovascular events (MI/HF/LTVA: myocardial infarction [MI], heart failure [HF], and life-threatening ventricular arrhythmia [LTVA]), and all-cause mortality. Additional end points were MI, LTVA, HF, and cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A neural network was developed to count PVCs from ECGs recorded during exercise (6 minutes) and recovery (1 minute) in 48 315 asymptomatic participants from UK Biobank. Associations were estimated using multivariable Cox proportional hazard models. Explorative studies were conducted in subgroups with cardiovascular magnetic resonance imaging data (n=6290) and NT-proBNP (N-terminal Pro-B-type natriuretic peptide) levels (n=4607) to examine whether PVC burden was associated with subclinical cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Mean age was 56.8±8.2 years; 51.1% of the participants were female; and median follow-up was 12.6 years. Low PVC counts during exercise and recovery were both associated with MI/HF/LTVA risk, independently of clinical factors: adjusted hazard ratio (HR), 1.2 (1-5 exercise PVCs, <i>P</i>&lt;0.001) and HR, 1.3 (1-5 recovery PVCs, <i>P</i>&lt;0.001). Risks were higher with increasing PVC count: HR, 1.8 (>;20 exercise PVCs, <i>P</i>&lt;0.001) and HR, 1.6 (>;5 recovery PVCs, <i>P</i>&lt;0.001). A similar trend was observed for all-cause mortality, although associations were only significant for high PVC burdens: HRs, 1.6 (>;20 exercise PVCs, <i>P</i>&lt;0.001) and 1.5 (>;5 recovery PVCs, <i>P</i>&lt;0.001). Complex PVC rhythms were associated with higher risk compared with PVC count alone. PVCs were also associated with incident HF, LTVA, and cardiovascular mortality, but not MI. In the explorative studies, high PVC burden was associated with larger left ventricular volumes, lower ejection fraction, and higher levels of NT-proBNP compared with participants without PVCs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: In this cohort of middle-aged and older adults, PVC count during submaximal exercise and recovery were both associated with MI/HF/LTVA, all-cause mortality, HF, LTVAs, and cardiovascular mortality, independent of clinical and exercise test factors, indicating an incremental increase in risk as PVC count rises. Complex PVC rhythms were associated with higher risk compared with PVC count alone. Underlying mechanisms may include the presence of subclinical cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37855144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37855144</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064633>10.1161/CIRCULATIONAHA.123.064633</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37855144</guid>
<pubDate>Thu, 19 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Stefan van Duijvenboden</dc:creator>
<dc:creator>Julia Ramírez</dc:creator>
<dc:creator>Michele Orini</dc:creator>
<dc:creator>Nay Aung</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:creator>Aiden Doherty</dc:creator>
<dc:creator>Andrew Tinker</dc:creator>
<dc:creator>Patricia B Munroe</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:date>2023-10-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects</dc:title>
<dc:identifier>pmid:37855144</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064633</dc:identifier>
</item>
<item>
<title>Performance of Thrombectomy-Capable, Comprehensive, and Primary Stroke Centers in Reperfusion Therapies for Acute Ischemic Stroke: Report From the Get With The Guidelines-Stroke Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37855118/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this study representing national US practice, CSCs and TSCs exceeded PSCs in key quality-of-care reperfusion metrics and outcomes, whereas TSCs and CSCs demonstrated a similar performance. With more than one-fifth of all EVT procedures during the study period conducted at PSCs, it may be desirable to explore national initiatives aimed at facilitating the elevation of eligible PSCs to a higher certification status.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 19. doi: 10.1161/CIRCULATIONAHA.123.066114. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The thrombectomy-capable stroke center (TSC) is a recently introduced intermediate tier of accreditation for hospitals at which patients with acute ischemic stroke receive care. The comparative quality and clinical outcomes of reperfusion therapies at TSCs, primary stroke centers (PSCs), and comprehensive stroke centers (CSCs) have not been well delineated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a retrospective, observational, cohort study from 2018 to 2020 that included patients with acute ischemic stroke who received endovascular thrombectomy (EVT) and intravenous thrombolysis reperfusion therapies at CSCs, TSCs, or PSCs. Participants were recruited from Get With The Guidelines-Stroke registry. Study end points included timeliness of intravenous thrombolysis and EVT, successful reperfusion, discharge destination, discharge mortality, and functional independence at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 84 903 patients, 48 682 received EVT, of whom 73% were treated at CSCs, 22% at PSCs, and 4% at TSCs. The median annual EVT volume was 76 for CSCs, 55 for TSCs, and 32 for PSCs. Patient differences by center status included higher National Institutes of Health Stroke Scale score, longer onset-to-arrival time, and higher transfer-in rates for CSCs, TSCs, and PSCs, respectively. In adjusted analyses, the likelihood of achieving the goal door-to-needle time was higher in CSCs compared with PSCs (odds ratio [OR], 1.39 [95% CI, 1.17-1.66]) and in TSCs compared with PSCs (OR, 1.45 [95% CI, 1.08-1.96]). Likewise, the odds of achieving the goal door-to-puncture time were higher in CSCs compared with PSCs (OR, 1.58 [95% CI, 1.13-2.21]). CSCs and TSCs also demonstrated better clinical efficacy outcomes compared with PSCs. The odds of discharge to home or rehabilitation were higher in CSCs compared with PSCs (OR, 1.18 [95% CI, 1.06-1.31]), whereas the odds of in-hospital mortality or discharge to hospice were lower in both CSCs compared with PSCs (OR, 0.87 [95% CI, 0.81-0.94]) and TSCs compared with PSCs (OR, 0.86 [95% CI, 0.75-0.98]). There were no significant differences in any of the quality-of-care metrics and clinical outcomes between TSCs and CSCs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study representing national US practice, CSCs and TSCs exceeded PSCs in key quality-of-care reperfusion metrics and outcomes, whereas TSCs and CSCs demonstrated a similar performance. With more than one-fifth of all EVT procedures during the study period conducted at PSCs, it may be desirable to explore national initiatives aimed at facilitating the elevation of eligible PSCs to a higher certification status.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37855118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37855118</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066114>10.1161/CIRCULATIONAHA.123.066114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37855118</guid>
<pubDate>Thu, 19 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Radoslav Raychev</dc:creator>
<dc:creator>Jie-Lena Sun</dc:creator>
<dc:creator>Lee Schwamm</dc:creator>
<dc:creator>Eric E Smith</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Steven R Messé</dc:creator>
<dc:creator>Ying Xian</dc:creator>
<dc:creator>Karen Chiswell</dc:creator>
<dc:creator>Rosalia Blanco</dc:creator>
<dc:creator>Brian Mac Grory</dc:creator>
<dc:creator>Jeffrey L Saver</dc:creator>
<dc:date>2023-10-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Performance of Thrombectomy-Capable, Comprehensive, and Primary Stroke Centers in Reperfusion Therapies for Acute Ischemic Stroke: Report From the Get With The Guidelines-Stroke Registry</dc:title>
<dc:identifier>pmid:37855118</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066114</dc:identifier>
</item>
<item>
<title>SARS-CoV-2 infects macrophages in coronary atherosclerotic plaques</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37853160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 18. doi: 10.1038/s41569-023-00949-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37853160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37853160</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00949-0>10.1038/s41569-023-00949-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37853160</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>SARS-CoV-2 infects macrophages in coronary atherosclerotic plaques</dc:title>
<dc:identifier>pmid:37853160</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00949-0</dc:identifier>
</item>
<item>
<title>Sirtuin 2 protects against cardiac ageing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37853159/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 18. doi: 10.1038/s41569-023-00950-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37853159/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37853159</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00950-7>10.1038/s41569-023-00950-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37853159</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Sirtuin 2 protects against cardiac ageing</dc:title>
<dc:identifier>pmid:37853159</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00950-7</dc:identifier>
</item>
<item>
<title>Reply: Loperamide-Associated Ventricular Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852701/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):e159. doi: 10.1016/j.jacc.2023.07.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852701/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852701</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.033>10.1016/j.jacc.2023.07.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852701</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mori J Krantz</dc:creator>
<dc:creator>Norman Stockbridge</dc:creator>
<dc:creator>David P Kao</dc:creator>
<dc:creator>Michael G Klein</dc:creator>
<dc:creator>Mark C P Haigney</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Loperamide-Associated Ventricular Arrhythmias</dc:title>
<dc:identifier>pmid:37852701</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.033</dc:identifier>
</item>
<item>
<title>Loperamide-Associated Ventricular Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):e157-e158. doi: 10.1016/j.jacc.2023.06.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852700</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.054>10.1016/j.jacc.2023.06.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852700</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonaz Font</dc:creator>
<dc:creator>Joachim Alexandre</dc:creator>
<dc:creator>Charles Dolladille</dc:creator>
<dc:creator>Paul Milliez</dc:creator>
<dc:creator>Pierre Ollitrault</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Loperamide-Associated Ventricular Arrhythmias</dc:title>
<dc:identifier>pmid:37852700</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.054</dc:identifier>
</item>
<item>
<title>The SCAI Shock Classification Has a New Home: The Cardiac Surgery Intensive Care Unit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852699/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):1707-1710. doi: 10.1016/j.jacc.2023.08.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852699/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852699</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.030>10.1016/j.jacc.2023.08.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852699</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jacob C Jentzer</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The SCAI Shock Classification Has a New Home: The Cardiac Surgery Intensive Care Unit</dc:title>
<dc:identifier>pmid:37852699</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.030</dc:identifier>
</item>
<item>
<title>Systematic Assessment of Shock Severity in Postoperative Cardiac Surgery Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The SCAI shock classification effectively risk-stratifies postoperative CSICU patients for mortality, postoperative complications, and organ dysfunction. Its application could, therefore, be extended to the field of cardiac surgery as a triage tool in postoperative care and as a selection criterion in research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):1691-1706. doi: 10.1016/j.jacc.2023.08.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Society for Cardiovascular Angiography and Interventions (SCAI) shock classification has been shown to provide robust mortality risk stratification in a variety of cardiovascular patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the SCAI shock classification in postoperative cardiac surgery intensive care unit (CSICU) patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study retrospectively analyzed 26,792 postoperative CSICU admissions at a heart center between 2012 and 2022. Patients were classified into SCAI shock stages A to E using electronic health record data. Moreover, the impact of late deterioration (LD) as an additional risk modifier was investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The proportions of patients in SCAI shock stages A to E were 24.4%, 18.8%, 8.4%, 35.5%, and 12.9%, and crude hospital mortality rates were 0.4%, 0.6%, 3.3%, 4.9%, and 30.2%, respectively. Similarly, the prevalence of postoperative complications and organ dysfunction increased across SCAI shock stages. After multivariable adjustment, each higher SCAI shock stage was associated with increased hospital mortality (adjusted OR: 1.26-16.59) compared with SCAI shock stage A, as was LD (adjusted OR: 8.2). The SCAI shock classification demonstrated a strong diagnostic performance for hospital mortality (area under the receiver operating characteristic: 0.84), which noticeably increased when LD was incorporated into the model (area under the receiver operating characteristic: 0.90).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The SCAI shock classification effectively risk-stratifies postoperative CSICU patients for mortality, postoperative complications, and organ dysfunction. Its application could, therefore, be extended to the field of cardiac surgery as a triage tool in postoperative care and as a selection criterion in research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852698</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.031>10.1016/j.jacc.2023.08.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852698</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Tobias Roeschl</dc:creator>
<dc:creator>Nils Hinrichs</dc:creator>
<dc:creator>Matthias Hommel</dc:creator>
<dc:creator>Boris Pfahringer</dc:creator>
<dc:creator>Felix Balzer</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Benjamin O'Brien</dc:creator>
<dc:creator>Sascha Christoph Ott</dc:creator>
<dc:creator>Evgenij Potapov</dc:creator>
<dc:creator>Felix Schoenrath</dc:creator>
<dc:creator>Alexander Meyer</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systematic Assessment of Shock Severity in Postoperative Cardiac Surgery Patients</dc:title>
<dc:identifier>pmid:37852698</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.031</dc:identifier>
</item>
<item>
<title>Multiparametric Nuclear Stress Imaging: The Whole Is Greater Than the Sum of its Parts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):1673-1675. doi: 10.1016/j.jacc.2023.08.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852697</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.029>10.1016/j.jacc.2023.08.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852697</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Edward A Hulten</dc:creator>
<dc:creator>Richard L Weinberg</dc:creator>
<dc:creator>Friederike K Keating</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Multiparametric Nuclear Stress Imaging: The Whole Is Greater Than the Sum of its Parts</dc:title>
<dc:identifier>pmid:37852697</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.029</dc:identifier>
</item>
<item>
<title>Impact of Positron Emission Tomographic Myocardial Perfusion Imaging on Patient Selection for Revascularization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A lack of augmentation or drop in LVEF with vasodilator stress on PET MPI independently identifies patients who have better survival with revascularization within 90 days post-MPI compared with medical therapy, in absence of prior myocardial infarction or revascularization. Multiparametric assessment of ischemia with PET can optimize post-test management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):1662-1672. doi: 10.1016/j.jacc.2023.08.027.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Positron emission tomography (PET) myocardial perfusion imaging (MPI) quantifies left ventricular ejection fraction (LVEF) at peak stress. PET LVEF reserve (LVEF-R = stress LVEF - rest LVEF) offers diagnostic and prognostic value.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine if PET LVEF-R identifies patients with survival benefit postrevascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We followed 14,649 unique consecutive patients undergoing <sup>82</sup>Rb rest/stress PET MPI from January 2010 to January 2016 (excluding known cardiomyopathy). Adjusted Cox models were built to predict all-cause death, and the 3-way interaction of known coronary artery disease (CAD) (prior myocardial infarction/revascularization), LVEF-R, and 90-day revascularization was tested.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Known CAD was present in 4,982 (34.0%). Ischemia was detected in 5,396 (36.8%; ≥10% in 1,909 [13%]). Mean LVEF-R was 4.2% ± 5.7%, and was ≤0, 1 to 5, and >;5 in 3,349 (22.9%), 5,266 (35.9%), and 6,034 (41.2%). Over median follow-up of 3.4 years (IQR: 1.9-5.2 years), 1,324 (8.1%) had 90-day revascularization, and there were 2,192 (15.0%) deaths. In multivariable modeling, there was a significant 3-way interaction among known CAD, LVEF-R, and 90-day revascularization (P = 0.025), such that LVEF-R ≤0 identified patients with survival benefit with 90-day revascularization in those without prior CAD (interaction P = 0.005), independently beyond percent ischemia and myocardial flow reserve. Among patients with known CAD, LVEF-R was not prognostic of death (HR: 0.99; 95% CI: 0.98-1.02; P = 0.98).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A lack of augmentation or drop in LVEF with vasodilator stress on PET MPI independently identifies patients who have better survival with revascularization within 90 days post-MPI compared with medical therapy, in absence of prior myocardial infarction or revascularization. Multiparametric assessment of ischemia with PET can optimize post-test management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852696</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.027>10.1016/j.jacc.2023.08.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852696</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Krishna K Patel</dc:creator>
<dc:creator>A Iain McGhie</dc:creator>
<dc:creator>Kevin F Kennedy</dc:creator>
<dc:creator>Randall C Thompson</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Brett W Sperry</dc:creator>
<dc:creator>Leslee J Shaw</dc:creator>
<dc:creator>Timothy M Bateman</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Positron Emission Tomographic Myocardial Perfusion Imaging on Patient Selection for Revascularization</dc:title>
<dc:identifier>pmid:37852696</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.027</dc:identifier>
</item>
<item>
<title>The Heart-Brain Connection in Myocardial Infarction in Women: A Dilemma to Tackle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):1659-1661. doi: 10.1016/j.jacc.2023.08.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852695</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.034>10.1016/j.jacc.2023.08.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852695</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Heart-Brain Connection in Myocardial Infarction in Women: A Dilemma to Tackle</dc:title>
<dc:identifier>pmid:37852695</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.034</dc:identifier>
</item>
<item>
<title>Psychosocial Factors of Women Presenting With Myocardial Infarction With or Without Obstructive Coronary Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852694/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Stress and depression are common among women at the time of and 2 months after MI. MINOCA patients were less likely to report high stress compared with MI-CAD patients, but the frequency of elevated depressive symptoms did not differ between the 2 groups. Stress and depressive symptoms decreased in both MI-CAD and MINOCA patients over time.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 24;82(17):1649-1658. doi: 10.1016/j.jacc.2023.08.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women with myocardial infarction (MI) are more likely to have elevated stress levels and depression than men with MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We investigated psychosocial factors in women with myocardial infarction with nonobstructive coronary arteries (MINOCA) and those with MI and obstructive coronary artery disease (CAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Women with MI enrolled in a multicenter study and completed measures of perceived stress (Perceived Stress Scale-4) and depressive symptoms (Patient Health Questionnaire-2) at the time of MI (baseline) and 2 months later. Stress, depression, and changes over time were compared between MI subtypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 172 MINOCA and 314 MI-CAD patients. Women with MINOCA were younger (age 59.4 years vs 64.2 years; P &lt; 0.001) and more diverse than those with MI-CAD. Women with MINOCA were less likely to have high stress (Perceived Stress Scale-4 ≥6) at the time of MI (51.0% vs 63.0%; P = 0.021) and at 2 months post-MI (32.5% vs 46.3%; P = 0.019) than women with MI-CAD. There was no difference in elevated depressive symptoms (Patient Health Questionnaire-2 ≥2) at the time of MI (36% vs 43%; P = 0.229) or at 2 months post-MI (39% vs 40%; P = 0.999). No differences in the rate of 2-month decline in stress and depression scores were observed between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Stress and depression are common among women at the time of and 2 months after MI. MINOCA patients were less likely to report high stress compared with MI-CAD patients, but the frequency of elevated depressive symptoms did not differ between the 2 groups. Stress and depressive symptoms decreased in both MI-CAD and MINOCA patients over time.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852694/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852694</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.028>10.1016/j.jacc.2023.08.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852694</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Anaïs Hausvater</dc:creator>
<dc:creator>Tanya M Spruill</dc:creator>
<dc:creator>Yuhe Xia</dc:creator>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:creator>Milla Arabadjian</dc:creator>
<dc:creator>Binita Shah</dc:creator>
<dc:creator>Ki Park</dc:creator>
<dc:creator>Caitlin Giesler</dc:creator>
<dc:creator>Kevin Marzo</dc:creator>
<dc:creator>Dwithiya Thomas</dc:creator>
<dc:creator>Janet Wei</dc:creator>
<dc:creator>Jeffrey Trost</dc:creator>
<dc:creator>Puja K Mehta</dc:creator>
<dc:creator>Bryan Har</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Hua Zhong</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Psychosocial Factors of Women Presenting With Myocardial Infarction With or Without Obstructive Coronary Arteries</dc:title>
<dc:identifier>pmid:37852694</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.028</dc:identifier>
</item>
<item>
<title>Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37852260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231020203606&amp;v=2.17.9.post6+86293ac
      <description>The complement system is a critical part of our innate immune response, and the terminal products of this cascade, anaphylatoxins C3a and C5a, exert their physiological and pathophysiological responses primarily via two GPCRs, C3aR and C5aR1. However, the molecular mechanism of ligand recognition, activation, and signaling bias of these receptors remains mostly elusive. Here, we present nine cryo-EM structures of C3aR and C5aR1 activated by their natural and synthetic agonists, which reveal...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 10:S0092-8674(23)01074-7. doi: 10.1016/j.cell.2023.09.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The complement system is a critical part of our innate immune response, and the terminal products of this cascade, anaphylatoxins C3a and C5a, exert their physiological and pathophysiological responses primarily via two GPCRs, C3aR and C5aR1. However, the molecular mechanism of ligand recognition, activation, and signaling bias of these receptors remains mostly elusive. Here, we present nine cryo-EM structures of C3aR and C5aR1 activated by their natural and synthetic agonists, which reveal distinct binding pocket topologies of complement anaphylatoxins and provide key insights into receptor activation and transducer coupling. We also uncover the structural basis of a naturally occurring mechanism to dampen the inflammatory response of C5a via proteolytic cleavage of the terminal arginine and the G-protein signaling bias elicited by a peptide agonist of C3aR identified here. In summary, our study elucidates the innerworkings of the complement anaphylatoxin receptors and should facilitate structure-guided drug discovery to target these receptors in a spectrum of disorders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37852260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231020203606&v=2.17.9.post6+86293ac">37852260</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.020>10.1016/j.cell.2023.09.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37852260</guid>
<pubDate>Wed, 18 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Manish K Yadav</dc:creator>
<dc:creator>Jagannath Maharana</dc:creator>
<dc:creator>Ravi Yadav</dc:creator>
<dc:creator>Shirsha Saha</dc:creator>
<dc:creator>Parishmita Sarma</dc:creator>
<dc:creator>Chahat Soni</dc:creator>
<dc:creator>Vinay Singh</dc:creator>
<dc:creator>Sayantan Saha</dc:creator>
<dc:creator>Manisankar Ganguly</dc:creator>
<dc:creator>Xaria X Li</dc:creator>
<dc:creator>Samanwita Mohapatra</dc:creator>
<dc:creator>Sudha Mishra</dc:creator>
<dc:creator>Htet A Khant</dc:creator>
<dc:creator>Mohamed Chami</dc:creator>
<dc:creator>Trent M Woodruff</dc:creator>
<dc:creator>Ramanuj Banerjee</dc:creator>
<dc:creator>Arun K Shukla</dc:creator>
<dc:creator>Cornelius Gati</dc:creator>
<dc:date>2023-10-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors</dc:title>
<dc:identifier>pmid:37852260</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.020</dc:identifier>
</item>





























</channel>
</rss>